Blaze Therapeutics' publications are protected under copyright law by the designated author(s). If you would like to utilize the information found in any of listed publication, you are bound by copyright laws to cite all references.
2020 Educational Guide - 8th Edition
Download the latest edition of the 2020 Educational Guide. While this publication is being provided to the public free of charge, it is protected by copyright laws and must be sited if referenced. If you are interested in partnering with Blaze Therapeutics to create scientifically accurate educational materials for the public, you may contact the Blaze team at email@example.com.
Classification of Residual Solvents
Residual solvents in therapeutics are defined as organic volatile chemicals that are used or produced in the manufacture of drug and/or supplement ingredients, or in the preparation of a therapeutic product. Some residual solvents are not completely removed by practical manufacturing techniques. However, because some residual solvents may be toxic at specific concentrations, it is critical that all plant-derived therapeutic products undergo testing in their final form before being distributed to the public.
DEA Public Letter 08/27/19
In this notice, the DEA announces that, as the result of a recent amendment to federal law, certain forms of cannabis no longer require DEA registration to grow or manufacture. The Agriculture Improvement Act of 2018, which was signed into law on Dec. 20, 2018, changed the definition of marijuana to exclude “hemp”—plant material that contains 0.3 percent or less delta-9 THC on a dry weight basis. Accordingly, hemp, including hemp plants and cannabidiol (CBD) preparations at or below the 0.3 percent delta-9 THC threshold, is not a controlled substance, and a DEA registration is not required to grow or research it.
Small Entity Compliance Guide: Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements
While the FDA does not currently classify CBD products as dietary supplements, manufacturers of CBD products derived from hemp operating under the Farm Bill Act of 2018 has an ethical duty to practice good manufacturing practices. Unfortunately, most manufacturers are not implementing GMP guidelines when manufacturing their products, which is why Blaze Therapeutics has implemented the Responsible Distribution model for the Cannabis Industry.
CANNABIDIOL (CBD) Pre-Review Report
by the Expert Committee on Drug Dependence of the World Health Organization (WHO)
This pre-review report provides a comprehensive review of CBD as of November 2017. While some of the information is out-dated, there are several timeless and reference-able information provided in this document.